Cargando…
Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials
Cancer is currently considered one of the most threatening diseases worldwide. Diet could be one of the factors that can be enhanced to comprehensively address a cancer patient’s condition. Unfortunately, most molecules capable of targeting cancer cells are found in uncommon food sources. Among them...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864405/ https://www.ncbi.nlm.nih.gov/pubmed/36677728 http://dx.doi.org/10.3390/molecules28020670 |
_version_ | 1784875576440389632 |
---|---|
author | Trinidad-Calderón, Plinio A. Varela-Chinchilla, Carlos Daniel García-Lara, Silverio |
author_facet | Trinidad-Calderón, Plinio A. Varela-Chinchilla, Carlos Daniel García-Lara, Silverio |
author_sort | Trinidad-Calderón, Plinio A. |
collection | PubMed |
description | Cancer is currently considered one of the most threatening diseases worldwide. Diet could be one of the factors that can be enhanced to comprehensively address a cancer patient’s condition. Unfortunately, most molecules capable of targeting cancer cells are found in uncommon food sources. Among them, depsipeptides have emerged as one of the most reliable choices for cancer treatment. These cyclic amino acid oligomers, with one or more subunits replaced by a hydroxylated carboxylic acid resulting in one lactone bond in a core ring, have broadly proven their cancer-targeting efficacy, some even reaching clinical trials and being commercialized as “anticancer” drugs. This review aimed to describe these depsipeptides, their reported amino acid sequences, determined structure, and the specific mechanism by which they target tumor cells including apoptosis, oncosis, and elastase inhibition, among others. Furthermore, we have delved into state-of-the-art in vivo and clinical trials, current methods for purification and synthesis, and the recognized disadvantages of these molecules. The information collated in this review can help researchers decide whether these molecules should be incorporated into functional foods in the near future. |
format | Online Article Text |
id | pubmed-9864405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98644052023-01-22 Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials Trinidad-Calderón, Plinio A. Varela-Chinchilla, Carlos Daniel García-Lara, Silverio Molecules Review Cancer is currently considered one of the most threatening diseases worldwide. Diet could be one of the factors that can be enhanced to comprehensively address a cancer patient’s condition. Unfortunately, most molecules capable of targeting cancer cells are found in uncommon food sources. Among them, depsipeptides have emerged as one of the most reliable choices for cancer treatment. These cyclic amino acid oligomers, with one or more subunits replaced by a hydroxylated carboxylic acid resulting in one lactone bond in a core ring, have broadly proven their cancer-targeting efficacy, some even reaching clinical trials and being commercialized as “anticancer” drugs. This review aimed to describe these depsipeptides, their reported amino acid sequences, determined structure, and the specific mechanism by which they target tumor cells including apoptosis, oncosis, and elastase inhibition, among others. Furthermore, we have delved into state-of-the-art in vivo and clinical trials, current methods for purification and synthesis, and the recognized disadvantages of these molecules. The information collated in this review can help researchers decide whether these molecules should be incorporated into functional foods in the near future. MDPI 2023-01-09 /pmc/articles/PMC9864405/ /pubmed/36677728 http://dx.doi.org/10.3390/molecules28020670 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Trinidad-Calderón, Plinio A. Varela-Chinchilla, Carlos Daniel García-Lara, Silverio Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials |
title | Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials |
title_full | Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials |
title_fullStr | Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials |
title_full_unstemmed | Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials |
title_short | Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials |
title_sort | depsipeptides targeting tumor cells: milestones from in vitro to clinical trials |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864405/ https://www.ncbi.nlm.nih.gov/pubmed/36677728 http://dx.doi.org/10.3390/molecules28020670 |
work_keys_str_mv | AT trinidadcalderonplinioa depsipeptidestargetingtumorcellsmilestonesfrominvitrotoclinicaltrials AT varelachinchillacarlosdaniel depsipeptidestargetingtumorcellsmilestonesfrominvitrotoclinicaltrials AT garcialarasilverio depsipeptidestargetingtumorcellsmilestonesfrominvitrotoclinicaltrials |